Acumen Pharmaceuticals ABOS Stock
Acumen Pharmaceuticals Price Chart
Acumen Pharmaceuticals ABOS Financial and Trading Overview
| Acumen Pharmaceuticals stock price | 2.29 USD |
| Previous Close | 2.6 USD |
| Open | 2.6 USD |
| Bid | 1.91 USD x 200 |
| Ask | 3.22 USD x 200 |
| Day's Range | 2.51 - 2.66 USD |
| 52 Week Range | 1 - 3.6 USD |
| Volume | 421.45K USD |
| Avg. Volume | 539.97K USD |
| Market Cap | 181.29M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.4 USD |
ABOS Valuation Measures
| Enterprise Value | 90.44M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6567438 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.0726674 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.789 |
Trading Information
Acumen Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 159.99% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.6 USD |
| 52 Week Low | 1 USD |
| 50-Day Moving Average | 2.54 USD |
| 200-Day Moving Average | 2.17 USD |
ABOS Share Statistics
| Avg. Volume (3 month) | 539.97K USD |
| Avg. Daily Volume (10-Days) | 352.32K USD |
| Shares Outstanding | 72.23M |
| Float | 37.01M |
| Short Ratio | 5.77 |
| % Held by Insiders | 6.67% |
| % Held by Institutions | 64.12% |
| Shares Short | 1.75M |
| Short % of Float | 3.47% |
| Short % of Shares Outstanding | 2.41% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.37% |
| Return on Equity (ttm) | -93.23% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -104885000 USD |
| EBITDA | -114556000 USD |
| Net Income Avi to Common (ttm) | -113276000 USD |
| Diluted EPS (ttm) | -1.85 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 128.4M USD |
| Total Cash Per Share (mrq) | 1.78 USD |
| Total Debt (mrq) | 31.05M USD |
| Total Debt/Equity (mrq) | 35.49 USD |
| Current Ratio (mrq) | 4.553 |
| Book Value Per Share (mrq) | 1.211 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -105545000 USD |
| Levered Free Cash Flow (ttm) | -67240624 USD |
Profile of Acumen Pharmaceuticals
| Country | United States |
| State | MA |
| City | Newton |
| Address | 1210-1220 Washington St. |
| ZIP | 02465 |
| Phone | 617 344 4190 |
| Website | https://acumenpharm.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 60 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Q&A For Acumen Pharmaceuticals Stock
What is a current ABOS stock price?
Acumen Pharmaceuticals ABOS stock price today per share is 2.29 USD.
How to purchase Acumen Pharmaceuticals stock?
You can buy ABOS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Acumen Pharmaceuticals?
The stock symbol or ticker of Acumen Pharmaceuticals is ABOS.
Which industry does the Acumen Pharmaceuticals company belong to?
The Acumen Pharmaceuticals industry is Biotechnology.
How many shares does Acumen Pharmaceuticals have in circulation?
The max supply of Acumen Pharmaceuticals shares is 72.23M.
What is Acumen Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Acumen Pharmaceuticals PE Ratio is now.
What was Acumen Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Acumen Pharmaceuticals EPS is -1.85 USD over the trailing 12 months.
Which sector does the Acumen Pharmaceuticals company belong to?
The Acumen Pharmaceuticals sector is Healthcare.
Acumen Pharmaceuticals ABOS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}